Larazotide
Based on 4 publication(s) in Google Scholar
Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.26%
- CAS No.: 258818-34-7
- Formule: C32H55N9O10
- Masse moléculaire:725.83
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Peptide Library
HY-L105
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Clinical Compound Library
HY-L026
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
-
Peptide Compound Library
HY-L105S
Publications Citing Use of MedChemExpress (MCE) Larazotide
More
Activité biologique
Larazotide (1-100 μM; 5 d) affects Vero cell growth[1]. Larazotide (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively[1]. Larazotide (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells[2]. Larazotide (100 μM; 3 h) inhibits gliadin translocation across Caco-2 monolayers[2]. Larazotide (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Vero cell line
-
Concentration:1-100 μM
-
Incubation Time:5 days
-
Result:Inhibited Vero cell growth with an CC50 value of 82.5 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HLA-HCD4/DQ8 double transgenic mice[2]
-
Dosage:250 μg
-
Administration:Intraperitoneal injection; 250 μg twice a week for 7 weeks
-
Result:Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 258818-34-7
-
Appearance Solid
-
Masse moléculaire 725.83
-
Formule C32H55N9O10
-
Color White to off-white
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. [Abstract]2020 Jun 19;11(1):3151. PMID: 32561730 -
EBioMedicine
Metallothionein 2 activation by pravastatin reinforces epithelial integrity and ameliorates radiation-induced enteropathy. [Abstract]2021 Nov:73:103641. PMID: 34688032 -
J Dent Res
2023 Jan;102(1):82-92. PMID: 36112881 -
JID Innov
The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis. [Abstract]2025 Apr 3;5(4):100369. PMID: 40330848
Solvant et solubilité
H2O : 2.5 mg/mL (3.44 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Di Micco S, et al. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. Int J Mol Sci. 2021 Aug 30;22(17):9427. [Content Brief]
[2]. Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35(1):86-94. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.3777 mL | 6.8887 mL | 13.7773 mL | 34.4433 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Larazotide Related Classifications
HY-106268 Related Classifications
Powered by Bioz